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Background: To report the 12 months follow up results of verteporﬁ  n therapy for subretinal 
neovascularization (SRNV) associated with type 2A parafoveal telangiectasia (PFT).
Methods: A Prospective interventional case series. Patients who completed 12 months follow 
up following photodynamic dynamic therapy with verteporﬁ  n for subretinal neovascularistion 
with Type 2A PFT were studied. All patients underwent visual acuity assessment with ETDRS 
letter acuity chart at 4 meters, slit lamp biomicroscopy, fundus ﬂ  uorescein angiography and 
photography. Treatment protocol of TAP study was followed. The follow up schedule was 
every month for 3 months and then every 3 months thereafter until 12 months. Primary out-
come measure was the change in visual acuity and secondary outcome measure was the mean 
treatment rate. Improvement was deﬁ  ned as  10 letters gain, stabilization as ± 10 letters and 
deterioration as  10 letters loss.
Results: Twelve eyes of 7 patients received photodynamic therapy with verteporﬁ  n for SRNV 
with Type 2A PFT. Initial mean letter acuity was 25.4 and 23.4 at 12months (p = 0.7). At 12 
months, one eye had  10 letters gain, 2 eyes had  10 letters loss and 9 had stabilized vision 
(± 10 letters). The mean number of treatment was 2.6. Ten (83.3%) of 12 eyes had retinal pig-
ment epithelial collateral change, observed at the end 12 months.
Conclusion: Photodynamic therapy with verteporﬁ  n is effective in stabilization of vision in 
SRNV associated with type 2A PFT.
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Introduction
Parafoveal telangiectasia is characterized by loss of retinal transparency, small tel-
angiectatic vessels, late ﬂ  uorescein dye leakage and cystic appearance to the fovea 
without intraretinal leakage. Typically, loss of retinal transparency appears grayish. 
(Gass and Blodi 1993)
Subretinal neovascularization (SRNV) is the most important cause of severe visual 
loss in patients with Type 2A parafoveal telangiectasia or Idiopathic juxtafoveal telen-
giectasia. (Gass and Blodi 1993) This accounts for 14% of the cases. Type 2A or Group 
2A have the most common form of parafoveal telangiectasia. Bilateral involvement 
is seen in more than 95% of patients at the time of presentation. In these patients, the 
telangiectatic change is often difﬁ  cult to detect biomicroscopically as it is associated 
with minimal exudation and retinal thickening. The cause of visual loss is primarily 
due to progressive foveolar atrophy and SRNV in minority of patients.
Treatment of SRNV in parafoveal telangiectasia by laser photocoagulation and 
surgery has been generally unsuccessful, associated with poor visual outcome (Gass and 
Blodi 1993; Lee 1996; Berger et al 1997). The primary complication during surgical 
removal is the shearing of the retina due to ﬁ  rm vascular anastomotic connection. Clinical Ophthalmology 2007:1(4) 484
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(Berger at al 1997) Hence, subretinal surgery is a relative 
contraindication in this subset of patients. In anecdotal series, 
transpupillary thermotherapy has shown encouraging results 
of either maintained or better vision in 88% of patients 
(Shukla et al 2004; Nachiappan et al 2005).
In the recent past, photodynamic therapy with vertepor-
ﬁ  n for SRNV has shown to be beneﬁ  cial in regression of 
SRNV and improvement of visual acuity (Potter et al 2002; 
Hershberger et al 2003; Smithen et al 2004; Hussain et al 
2005) Most of these case series had follow up of at least 7 
to 9 months (Potter et al 2002; Smithen et al 2004; Hussain 
et al 2005) except a single case report of bilateral involvement 
had 21 months follow up (Hershberger et al 2003). Snyers 
et al (2004) also showed effective treatment with verteporﬁ  n 
in 3 eyes with follow up of 23, 21 and 9 months. The com-
mon feature amongst all the published reports suggests that 
repeated treatment is necessary to achieve closure of the 
subretinal new vessels.
We report 12 months follow up outcome of photodynamic 
therapy with verteporﬁ  n for SRNV associated with Type 2A 
parafoveal telangiectasia.
Methods
Patients were recruited from the prospective patient enroll-
ment for photodynamic therapy with verteporﬁ  n in a tertiary 
care hospital. The study duration was between May 2001 and 
July 2005. The photodynamic therapy was approved by the 
ethics committee of the institution in 2001. Patients were 
explained about the long-term unproven nature of treatment 
for this subset of disease and informed consent was taken 
accordingly.
Patients diagnosed as subretinal neovascularisation asso-
ciated with type 2A parafoveal telangiectasia were included 
in the study. Any vascular or non-vascular causes that may 
adversely affect the macula were excluded from the study.
All patients underwent routine ocular examination which 
included ETDRS visual acuity measurement at 4 metres, Slit 
lamp biomicroscopy, Amsler grid and fundus examination 
(90/78 D and indirect ophthalmoscopy). Fundus photography 
and fundus ﬂ  uorescein angiography (FFA) was done in all 
patients in each visit and pretreatment. FFA was done using a 
con focal scanning laser ophthalmoscope (HRA, Heidelberg 
Engineering Inc., Heidelberg, Germany) by trained optom-
etrists. The follow up schedule was every month for 3 months 
then every three months thereafter following treatment.
Photodynamic therapy (PDT) was performed using 
verteporﬁ  n (Visudyne® 15 mgm, Novartis ophthalmics AG, 
Hettlingen, Suiza) following the protocol of TAP study (TAP 
Study Group 1999). A mainster focal contact lens (Ocular 
Instruments, USA) was used for viewing the fundus during 
PDT. In bilateral treatment, after completion of the ﬁ  rst eye, 
the lens was shifted to the contralateral eye within 20 minutes 
of start of infusion as described earlier (Hussain et al 2005). 
The eye with more active or larger lesion was treated ﬁ  rst 
than the contralateral eye (Hussain et al 2005).
Retreatment was done whenever there was evidence of 
leakage associated with retinal thickening. Care was taken 
not to misinterpret the underlying leakage pattern of the 
primary disease. 5400 micron was taken as the maximum 
permissible greatest linear dimension to be eligible for 
treatment.
Improvement was deﬁ  ned as 10 letters gain, deterio-
ration as 10 letters loss and stabilization as ± 10 letters 
change. The primary outcome measure was the change in 
visual acuity at the end of 12 months and the secondary 
outcome measure was the mean number of treatment sessions 
in each eye in one year.
Statistical analysis
A Wilcoxon signed rank test was done to ﬁ  nd out the sig-
niﬁ  cance of change in letter visual acuity seen till end of 
12 months from the baseline.
Results
Twelve eyes of 7 patients were included in the analysis 
(Table 1). Five of 7 patients had bilateral involvement. The 
mean age was 53.6 ± 7.6 years (Range: 42 to 63 years). The 
male female ratio was 3:4. The initial greatest linear diam-
eter of the SRNV ranged from 860 to 5740 (mean: 2990) 
microns. All the eyes had subfoveal neovascular membrane. 
All patients completed atleast 12 months follow up.
Letter acuity
The initial mean letter acuity was 25.4 letters with ﬁ  nal 
mean letter acuity of 23.4 letters at 12 months (p = 0.7, 
standard error: 3.2), which was not statistically signiﬁ  cant. 
Figure 1 shows a minimal trend of improvement in letter 
acuity at 3 months and then stabilization at 12 months with 
mean difference of 2 letters only. At 12 months, one eye 
gain  10 letters, 2 eyes lost  10 letters and 9 eyes (75%) 
had stabilized vision. 33% (4 eyes) had initial visual acuity 
of  20/40.
Snellen acuity
At 12 months, one eye (8.3%) had VA  20/40 and 7 eyes 
(58.3%) had between 20/50 and 20/80. 4 eyes remained Clinical Ophthalmology 2007:1(4) 485
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same at  20/200 as the initial VA even at twelve months. 
Figure 2 shows that the group of eyes that had VA between 
20/100 and 20/200 remained the same and 7 eyes had 
VA  20/80.
It can be concluded from Figures 1 and 2 that follow-
ing PDT with verteporﬁ  n, there is a trend towards mild 
visual loss ( 5 letters) with stabilization of vision at 12 
months.
Treatment sessions
The time and number of treatment sessions were shown 
in Figure 3. The patients received a total of 31 treatment 
Table 1 Clinical characteristics of patients with subretinal neovascularization and parafoveal telengiectasis
Sl no  OD/OS  Age/Sex  Initial VA  ETDRS  3rd mth VA  ETDRS  6th mth VA  ETDRS  12th mth VA  ETDRS  RPE coll.
        letters   letters   letters   letters
1  OD  54/M  20/100  17 20/80  22 20/80  22 20/80  21 + 
   OS     20/80  25  20/63  27  20/63  30  20/80  23   
2  OD  62/F  20/200  3 20/200 3 20/200  3 20/200 2  
   OS     20/80  23  20/100  18  20/100  18  20/100  20  +
3  OD  56/F  20/40  40 20/40  40 20/50  35 20/50  33 +
   OS     20/63  29  20/50  33  20/63  30  20/63  27  +
4  OD  51/F  20/50  35 20/50  35 20/50  35 20/32  44 +
   OS     20/200  3  20/100  18  20/160  7  20/125  13  +
5  OD  42/F  20/25  47 20/40  40 20/40  40 20/80  22 +
   OS     20/32  45  20/40  40  20/40  39  20/63  30  +
6  OS 63/M  20/125  12 20/125  16 20/125 13 20/125  13 +
7  OS 47/M  20/40  26 20/50  35 20/63  24 20/50  33 +
Abbreviations: OD, right eye; OS, left eye; M, male; F, female; mth, month; RPE coll, retinal pigment epithelial collateral damage.
Figure 1 Graph showing change in mean letter acuity in 12 months period. The change in letter was not statistically signiﬁ  cant (p = 0.7).
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sessions with a mean of 2.6 for each eye. 28 of 31 
treatment sessions (93.5%) were done within 6 months 
suggesting repeated and shorter interval of treatment is 
necessary.
Retinal pigment epithelial collateral damage from the 
baseline characteristics was seen in 10 eyes (83.3%) till 
the end of 12 months. The change has been seen around 
the SRNV and within the area of the spot size. No adverse 
ocular or systemic ocular events were observed during the 
follow up period.
Discussion
Subretinal neovascularisation may occur in advanced stages 
of primarily bilateral parafoveal telangiectasia (Stage 5, 
Type 2A) (Gass and Blodi 1993; Lee 1996). Management 
options in this subset of eyes are limited and studies have 
already shown the adverse outcome and limitations of 
medical and surgical treatment (Berger et al 1997; TAP 
Study Group 1999; Potter et al 2002; Hershberger et al 2003; 
Shukla et al 2004; Smithen et al 2004; Snyers et al 2004; 
Hussain et al 2005; Nachiappan et al 2005). The difﬁ  culty 
lies in the inability to achieve easy closure of the neovascular 
membrane. This is due to different internal milieu and origin 
of subretinal neovascular membrane (Gass 2003; Hussain 
et al 2005) than seen in neovascular membrane secondary to 
age related macular degeneration or myopia or etc.
Present study has shown that photodynamic therapy with 
verteporﬁ  n is effective in maintaining vision atleast till 12 
months of follow up. This result also suggest that PDT can 
prevent moderate to severe visual loss and better the initial 
VA, better is the outcome in maintaining vision. Syners et al 
(2004) have also reported similar results in maintenance of 
vision in 4 eyes (4 patients). Except in one eye where vision 
deteriorated to 20/200. The average follow up in these 4 
patients were 16.7 months.
The reason for apparent non-improvement of vision in the 
study was possibly due to associated retinal pigment epithe-
lial (RPE) collateral damage seen (83.3%) around the lesion 
following PDT. This ﬁ  nding was also shown in the earlier 
reports. (Potter et al 2002; Hussain et al 2005; Shanmugam 
2005) It is possible that the microvascular abnormality of 
telangiectasia vessels besides the SRNV may leak verteporﬁ  n 
Figure 2 Bar diagram showing Pre- and post-PDT snellens visual acuity in 12 months. 66.6% of eyes had VA  20/80 at baseline and 12 months.
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and theoretically may cause collateral change at the level of 
RPE. (Hussain et al 2005) This is a speciﬁ  c possibility due 
to leakage of verteporﬁ  n and frequent repeated treatment in 
these subsets of eyes.
The mean number of treatment was 2.6 in the present 
study, which is more than that treated for choroidal neovas-
cularization secondary to age related macular degeneration 
(mean: 2.1 at the end of 12 months) (Hussain et al 2006) in 
the eyes of similar ethnic origin. It has also been seen that 
93.5% of the eyes required treatment session within 6 months. 
Most of the small series of patients and case report with less 
than one year follow up published so far suggest number of 
treatment sessions ranging from 2 to 4 (mean 2.2) (Potter et al 
2002; Hershberger et al 2003; Smithen et al 2004; Snyers et al 
2004; Hussain et al 2005) which is also seen in the present 
series of patients. The highlight of PDT in PFT with SRNV 
can be stated that frequent repeated treatment is necessary 
to achieve successful closure. This may be attributed to the 
high ﬂ  ow microvascular connections to the subretinal lesions 
(Hussain et al 2005).
It has recently been shown that transpupillary thermo-
therapy (TTT) is effective in closure of SRNV associated 
with parafoveal telengiectasis. (Shukla et al 2004; Nachiap-
pan et al 2005; Shanmugam 2005) The two anecdotal series 
also shows that visual acuity can be maintained following 
TTT. However, RPE collateral damage has not been reported. 
The long-term thermal effect of TTT cannot be ruled out on 
an already compromised RPE associated with PFT.
Figure 3 Flow chart showing the time of treatment sessions in 12 months. 93.5% of the treatments were done within 6 months.
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Hence, photodynamic therapy with verteporfin is 
effective in successful closure of SRNV and stabilization 
of vision atleast at the end of 12 months. The limitations of 
the study are small sample size and long-term outcome or 
recurrence is not known. We feel the sample size of (12 eyes) 
appears adequate to see the effect at 12 months, as this entity 
with SRNV is also a rare clinical ﬁ  nding. We do agree that 
a long-term follow up study is also necessary.
Note
Financial interest: None.
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